Because it is classed as a cosmetic rather than a medical treatment, it has not been through the same safety and efficacy testing as regulated fat reduction options
Typically, this translates to 0.4 mg
Yang S, Lin C, Zhuo X, Wang J, Rao S, Xu W et al (2020) Glucagon-like peptide-1 alleviates diabetic kidney disease through activation of autophagy by regulating AMP-activated protein kinase-mammalian target of rapamycin pathway
This does not make the peptide a routine aesthetic treatment
Unfortunately, these interventions strongly depend on patient persistence, with even temporary gaps in treatment observed to rapidly reverse any weight improvements
This approach differs from the usual strategy of screening the published literature for reports of adverse effects